Epidemiology, Mechanisms, and Clinical Challenges of Respiratory Syncytial Virus Co-infections in Children

Respiratory syncytial virus (RSV) infection remains a leading cause of respiratory illness in infants and young children worldwide, with no widely available specific treatment. Advances in diagnostic technologies have increased the detection rate of RSV co-infections, but their impact on disease outcomes remains controversial. This work examines the epidemiological characteristics, clinical implications, and potential mechanisms of RSV co-infections. Findings indicate that RSV co-infections with bacteria or adenoviruses lead to more severe clinical symptoms and more complex treatment, while co-infections with other viruses may prolong illness without increasing severity. The specific mechanisms underlying RSV co-infections are still poorly understood. In recent years, significant breakthroughs in RSV vaccine and long-acting monoclonal antibody development have provided new tools for active prevention. Future research should focus on clarifying the molecular mechanisms of co-infections, developing targeted therapeutic drugs and vaccines, and optimizing diagnostic and treatment strategies to reduce the incidence and mortality of RSV-related diseases.

呼吸道合胞病毒（Respiratory syncytial virus, RSV）感染仍是全球婴幼儿呼吸道疾病的首要致病原因，目前尚无广泛可用的特异性治疗手段。诊断技术的进步提升了RSV合并感染的检出率，但其对疾病转归的影响仍存在争议。本研究针对RSV合并感染的流行病学特征、临床意义及潜在致病机制展开分析。研究结果显示，RSV与细菌或腺病毒的合并感染会导致更严重的临床症状及更复杂的治疗方案；而与其他病毒的合并感染则可能延长病程，但不会加重病情严重程度。RSV合并感染背后的具体致病机制目前仍不甚明确。近年来，RSV疫苗及长效单克隆抗体研发领域取得的重大突破，为主动预防提供了全新手段。未来的研究应聚焦于阐明合并感染的分子机制、开发针对性治疗药物与疫苗，以及优化诊疗策略，以降低RSV相关疾病的发病率与死亡率。